Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Davoceticept - Alpine Immune Sciences

Next Previous
X
Search
Drug Profile

Davoceticept - Alpine Immune Sciences

Alternative Names: ALPN-202; PD-1/CTLA-A Antagonist and CD28 Agonist - Alpine Immune Sciences

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alpine Immune Sciences
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV, Infusion)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top